PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.
Oncoimmunology
; 12(1): 2267744, 2023.
Article
in En
| MEDLINE
| ID: mdl-37868689
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Urinary Bladder Neoplasms
/
Carcinoma, Transitional Cell
/
Promoter Regions, Genetic
/
Immunotherapy
Limits:
Humans
Language:
En
Journal:
Oncoimmunology
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: